Update in the Management of ANCA-Associated Vasculitis: Recent Developments and Future Perspectives

Karla N Samman; Carolyn Ross; Christian Pagnoux; Jean-Paul Makhzoum

doi:10.1155/2021/5534851

Update in the Management of ANCA-Associated Vasculitis: Recent Developments and Future Perspectives

Int J Rheumatol. 2021 Apr 8:2021:5534851. doi: 10.1155/2021/5534851. eCollection 2021.

Authors

Karla N Samman¹, Carolyn Ross¹, Christian Pagnoux², Jean-Paul Makhzoum¹

Affiliations

¹ Vasculitis Clinic, Canadian Network for Research on Vasculitides (CanVasc), Division of Internal Medicine, Hôpital du Sacré-Coeur de Montréal, University of Montreal, Montreal, Quebec, Canada.
² Vasculitis Clinic, Canadian Network for Research on Vasculitides (CanVasc), Division of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada.

Abstract

Significant progress has been made in the treatment of ANCA-associated vasculitides (AAV), notably in granulomatosis with polyangiitis and microscopic polyangiitis. Over the past few years, many innovative studies have changed the way we now induce and maintain remission in AAV; achieving remission while limiting treatment toxicity is the key. This article provides an in-depth, up-to-date summary of recent trials and suggests treatment algorithms for induction and maintenance of remission based on the latest guidelines. Future possible therapies in AAV will also be discussed.

Publication types

Review